Elbasvir/grazoprevir plus sofosbuvir in treatment-naive and treatment-experienced cirrhotic patients with hepatitis C virus genotype 3 infection treated for 8, 12, or 16 weeks: final results of the C-ISLE study
Foster, G.R, Agarwal, K, Cramp, M.E, Moreea, S, Barclay, S, Collier, J, Brown, A.S, Ryder, S.D, Ustianowski, A, Forton, D.M, Fox, R, Gordon, F, Rosenberg, W.M, Mutimer, D.J, Du, J, Gilbert, C.L, Robertson, M, Barr, E, Haber, B
Published in Journal of hepatology (2017)
Published in Journal of hepatology (2017)
Get full text
Journal Article
Successful treatment of patients with HCV GT3 infection and cirrhosis with elbasvir/grazoprevir plus sofosbuvir does not correct insulin resistance by 12 weeks post-treatment
Foster, G, Agarwal, K, Cramp, M.E, Moreea, S, Barclay, S, Collier, J, Brown, A.S, Ryder, S.D, Ustianowski, A, Forton, D.M, Fox, R, Gordon, F, Rosenberg, W.M, Mutimer, D.J, Du, J, Gilbert, C.L, Robertson, M, Barr, E, Haber, B
Published in Journal of hepatology (2017)
Published in Journal of hepatology (2017)
Get full text
Journal Article
86 ABSENCE OF PROTECTION IN INDIVIDUALS EXPOSED TO HEPATITIS C VIRUS DEMONSTRATES DISCRETE GENETIC PATHWAYS FOR PROTECTION AGAINST CHRONIC HCV INFECTION
Knapp, S, Ho, K.M, Warshow, U, Heqazy, D, Little, A.-M, Alexander, G, Thursz, M, Cramp, M.E, Khakoo, S.I
Published in Journal of hepatology (01.03.2011)
Published in Journal of hepatology (01.03.2011)
Get full text
Journal Article
FRI-215 - Successful treatment of patients with HCV GT3 infection and cirrhosis with elbasvir/grazoprevir plus sofosbuvir does not correct insulin resistance by 12 weeks post-treatment
Foster, G., Agarwal, K., Cramp, M.E., Moreea, S., Barclay, S., Collier, J., Brown, A.S., Ryder, S.D., Ustianowski, A., Forton, D.M., Fox, R., Gordon, F., Rosenberg, W.M., Mutimer, D.J., Du, J., Gilbert, C.L., Robertson, M., Barr, E., Haber, B.
Published in Journal of hepatology (2017)
Published in Journal of hepatology (2017)
Get full text
Journal Article
FRI-213 - Elbasvir/grazoprevir plus sofosbuvir in treatment-naive and treatment-experienced cirrhotic patients with hepatitis C virus genotype 3 infection treated for 8, 12, or 16 weeks: final results of the C-ISLE study
Foster, G.R., Agarwal, K., Cramp, M.E., Moreea, S., Barclay, S., Collier, J., Brown, A.S., Ryder, S.D., Ustianowski, A., Forton, D.M., Fox, R., Gordon, F., Rosenberg, W.M., Mutimer, D.J., Du, J., Gilbert, C.L., Robertson, M., Barr, E., Haber, B.
Published in Journal of hepatology (2017)
Published in Journal of hepatology (2017)
Get full text
Journal Article
Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection
Hegazy, D, Thurairajah, P, Metzner, M, Houldsworth, A, Shaw, S, Kaminski, E, Demaine, A.G, Cramp, M.E
Published in Clinical and experimental immunology (01.06.2008)
Published in Clinical and experimental immunology (01.06.2008)
Get full text
Journal Article